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COMMENTARY
Turning a new page on nucleostemin and self-renewal
Robert Y. L. Tsai*
ABSTRACT
A quintessential trait of stem cells is embedded in their ability to self-
renew without incurring DNA damage as a result of genome
replication. One key self-renewal factor is the nucleolar GTP-
binding protein nucleostemin (also known as guanine-nucleotide-
binding protein-like 3, GNL3, in invertebrate species). Several studies
have recently pointed to an unexpected role of nucleostemin in
safeguarding the genome integrity of stem and cancer cells. Since its
discovery, the predominant presence of nucleostemin in the
nucleolus has led to the notion that it might function in the card-
carrying event of the nucleolus – the biogenesis of ribosomes. As
tantalizing as this might be, a ribosomal role of nucleostemin is
refuted by evidence from recent studies, which argues that
nucleostemin depletion triggers a primary event of DNA damage in
S phase cells that then leads to ribosomal perturbation. Furthermore,
there have been conflicting reports regarding the p53 dependency of
nucleostemin activity and the cell cycle arrest profile of nucleostemin-
depleted cells. In this Commentary, I propose a model that explains
how the many contradictory observations surrounding nucleostemin
can be reconciled and suggest that this protein might not be as multi-
tasking as has been previously perceived. The story of nucleostemin
highlights the complexity of the underlying molecular events
associated with the appearance of any cell biological phenotype
and also signifies a new understanding of the genome maintenance
program in stem cells.
KEY WORDS: Cell cycle arrest, DNA damage, p53, Nucleolus,
Nucleostemin, GNL3, Ribosomal synthesis, Self-renewal, Stem cell
Introduction
The nucleolus is a well-recognized intranuclear organelle that
functions in ribosome biogenesis. Increasingly, within recent years,
nucleolar or ribosomal proteins have been reported to play dual
roles in regulating the DNA damage response and repair as well as
ribosomal synthesis (Antoniali et al., 2014). The emerging link
between the nucleolus and genome maintenance (or other non-
ribosomal events) makes it ever more challenging to determine the
causative versus associative relationship between the non-
ribosomal (e.g. DNA damage) and ribosomal phenotypes
following a single event of gene perturbation. Does one lead to
the other and, if so, which comes first? Or, do they occur
independently? As the readout in any cell-centered study, be it
based on a single cell or a population of cells, represents an
integration of events that have happened up to the point of
measurement, it should come as no surprise that the outcome of
gene perturbation often varies in a cell-context-dependent manner
that might seem paradoxical at first, but can be logically explained
once all the pathways affected, either directly or indirectly, are
considered. However, too often those variations are simply
interpreted as yet ‘one more function of a multi-tasking protein’,
a good example of which is the nucleolar protein nucleostemin.
This Commentary attempts to resolve three existing debates on this
molecule and uses our journey with nucleostemin (also known as
guanine-nucleotide-binding protein-like 3, GNL3, in invertebrate
species) to highlight how one perturbed function might be read
differently by cells in more subtle ways than commonly perceived
and reveal a new understanding of the self-renewal maintenance of
stem cells and cancer cells.
History and mysteries
Nucleostemin was discovered because of its high expression in
neuroepithelial stem or progenitor cells purified from the fetal
forebrain (Tsai and McKay, 2002) and was later found to be
highly expressed in other types of stem cells, tumors, and tumor-
initiating cells or cancer stem cells (CSCs) (Baddoo et al., 2003;
Lin et al., 2010; Ohmura et al., 2008; Tamase et al., 2009; Tsai
and McKay, 2002; Yamashita et al., 2013). By contrast, in
differentiated cells and tissues, this protein is expressed at a much
lower level, except for those undergoing regeneration (Lin et al.,
2013; Maki et al., 2007; Shugo et al., 2012; Siddiqi et al., 2008).
It is a nucleolar protein that encodes four circularly permuted
GTP-binding (CPG) motifs and undergoes rapid exchange
between the nucleolar and nucleoplasmic compartments (Meng
et al., 2006; Tsai and McKay, 2005) (see Box 1 for detail). Unlike
its orthologs in yeast (Nug1) and fly (Ns1), the GTP hydrolysis
(GTPase) activity of mammalian nucleostemin has always been
assumed based on its GTP-binding property but never been
experimentally shown. The lack of evidence of an intrinsic
GTPase activity in mammalian nucleostemin might be due to the
fact that this protein is highly unstable (R.T., personal
observation) or the need of a yet unidentified GTPase-
activating protein. Regardless, until such evidence is presented,
it is scientifically inaccurate to refer to mammalian nucleostemin
as a nucleolar GTPase or assume it functions as a GTPase
enzyme. The biological importance of nucleostemin has never
been in doubt, as it is well established that nucleostemin makes
key contributions to blastocyst formation (Beekman et al., 2006;
Zhu et al., 2006), embryogenesis (Meng et al., 2013), postnatal
tissue regeneration (Lin et al., 2013; Shugo et al., 2012), cancer
development (Lin et al., 2010; Sijin et al., 2004; Tamase et al.,
2009) and reprograming to pluripotency (Qu and Bishop, 2012).
In contrast, the fundamental mechanism through which
nucleostemin functions is less clear. Despite considerable
interest, a consensus on this subject remains to be reached.
However, within the past two years, several studies have been
published that reveal the molecular mechanism of nucleostemin
in reducing DNA damage on the telomeres and non-telomeric
chromosomes. One study has shown that nucleostemin is able to
reduce telomere damage through modification of telomeric repeat
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binding factor 1 (TRF1, also known as TERF1) and recruitment
of promyelocytic leukemia protein isoform IV (PML-IV) in
telomerase-negative human cancer cells (Hsu et al., 2012). Two
reports have identified that it protects the genome integrity of
stem or progenitor cells by promoting the recruitment of RAD51,
the core component of the homologous recombination machinery,
to stalled replication-induced DNA damage foci (Lin et al., 2013;
Meng et al., 2013) (Fig. 1). Another study confirms its genome
protective role in hematopoietic stem cells (HSCs) and its
importance in maintaining the self-renewal of HSCs in vitro and
in vivo (Yamashita et al., 2013). For the genome- or telomere-
protective activity of nucleostemin, the nucleolus serves primarily
a storage or sequestration role. What is interesting about these
findings is that this genome- or telomere-protective role of
nucleostemin offers a potential hypothesis that best unifies most
of its in vitro and in vivo activities that have been reported to date,
as discussed below. However, the road leading to this recent
revelation is nothing but long and winding, as one has to plow
through the various activities of nucleostemin that have been
previously reported (e.g. p53 regulation, ribosomal synthesis and
cell cycle regulation) and potentially more in the making.
Nucleostemin – a Jack of all trades or not?
Because of its nucleolar presence, there has always been an
inclination to associate nucleostemin with ribosome biogenesis.
Indeed, deletions of the nucleostemin orthologs in fission yeast,
nematode and fruit fly have all been shown to reduce ribosomal
production, either with or without interfering with the
transcription or splicing of rRNAs (Du et al., 2006; Kudron and
Reinke, 2008; Rosby et al., 2009). Two studies have reported a
perturbed ribosomal effect following the knockdown of vertebrate
nucleostemin in zebrafish and in human cancer cells (Essers et al.,
2014; Romanova et al., 2009). Although these findings might
appear to be consistent with a role of nucleostemin in ribosomal
synthesis, there have been multiple lines of evidence that
contradict a direct involvement of mammalian nucleostemin in
ribosomal synthesis, including the failure of human nucleostemin
to rescue the ribosomal phenotype of yeast null for GNL3 (the
ortholog of nucleostemin), the non-congruent localization of
nucleostemin and nascent 28S rRNA inside the human nucleolus,
and the late occurrence of ribosomal defects following
nucleostemin knockdown (Du et al., 2006; Kudron and Reinke,
2008; Lin et al., 2014; Politz et al., 2005). Whether nucleostemin
has a ribosomal or non-ribosomal role is not the only issue under
debate. Earlier studies have indicated that nucleostemin (mostly
that of the mammal) is functionally linked to the p53 pathway and
physically associated with MDM2, the negative regulator of p53
(Dai et al., 2008; Ma and Pederson, 2007; Meng et al., 2008; Tsai
and McKay, 2002). However, the necessity of p53 in mediating
the obligatory function of nucleostemin has been disputed by
several independent studies that establish the indispensable role
of nucleostemin in maintaining the continuous proliferation of
cells that lack a functional p53 pathway (Beekman et al., 2006;
Jafarnejad et al., 2008; Meng et al., 2013). Finally, even at the
most basic and fundamental level, as is in all cell biological
studies, consensus has yet to be reached on how loss of
nucleostemin affects the cell cycle profile. Evidence linking
nucleostemin depletion to any of the possible cell cycle arrest
profiles (i.e. G1/S, intra-S, G2/M and mitotic arrest) can be found
in the published literature (a point to be further illustrated later).
If we believe that all the above studies are properly executed and
reproducible, and that biology is not governed by random
variables and probability, then how can we make sense of these
contradictory findings? Is nucleostemin so ‘multi-talented’ or
‘permissive’ that opposite effects might be possible for a single
event of nucleostemin perturbation? Or are those different
outcomes of perturbation merely reflective of the complexity of
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Fig. 1. Genome-protective role of nucleostemin.
Shown here is a schematic illustration of the role of
nucleostemin in the repair of replication-induced DNA
damage on interstitial chromosomes and in the repair of
telomere damage. The genome protective function of
nucleostemin promotes the recruitment of the core
homologous recombination protein, RAD51, which also
requires breast cancer susceptibility gene 2 (BRCA2),
Bloom syndrome protein (BLM), replication protein A
(RPA) and RAD52. For damaged telomeres,
nucleostemin regulates telomeric repeat binding factor 1
(TRF1) sumoylation and its subsequent association with
promyelocytic leukemia protein isoform IV (PML-IV),
which brings RAD51 to damaged telomeres for repair in
telomerase-negative cancer cells.
Box 1. Nucleolar localization and dynamic shuttling
of nucleostemin
The translocation of nucleostemin between the nucleolar and
nucleoplasmic compartments has been studied by chemical
perturbation and mutation analysis (Meng et al., 2007; Tsai and
McKay, 2005). Nucleostemin protein contains a stretch of basic
residues at its N-terminus that functions as a nucleolar localization
signal (NoLS). However, this basic NoLS can only confer a static
nucleolar distribution; alone it cannot recapitulate the dynamic
properties of the full-length nucleostemin, that is a long retention
time in the nucleolus. These additional features require the GTP-
binding domain of nucleostemin. The static accumulation and
dynamic movement of nucleostemin is controlled by another
domain that favors its nucleoplasmic localization. A key signal
that controls the nucleolar trafficking of nucleostemin is GTP, which
acts as a molecular switch to turn off the nucleoplasmic-anchoring
activity. The nucleoplasmic distribution of non-GTP-bound
nucleostemin mutants can be reversed back to the nucleolus by
inhibiting the 26S-proteasome-mediated protein degradation
pathway, suggesting that the degradation of nucleostemin protein
is coupled to its nucleoplasmic distribution through GTP binding
(Huang et al., 2009).
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cells? Based on my understanding of nucleostemin, those seemly
unrelated and at times contradictory observations might be the
work of a multi-tasking cell rather than a multi-tasking gene.
The end does not always justify the means
A potential role of human nucleostemin in ribosomal synthesis
was first claimed by a study that observed a delayed processing of
32S pre-rRNA to 28S rRNA and a reduction of 60S ribosomes in
HeLa cells in which nucleostemin has been knocked down
(Romanova et al., 2009). However, studies published by two
independent groups argue that rRNA processing might not be the
primary target of nucleostemin knockdown in human cells. One
group showed that human nucleostemin is localized in
subnucleolar regions that are deficient in nascent 28S rRNA
(Politz et al., 2005). The other group found that knockdown of
nucleostemin does not perturb the splicing of pre-rRNAs
(supplementary data shown at http://www.ribogenesis.com;
Tafforeau et al., 2013). It is worth noting that in the Romanova
et al. study (Romanova et al., 2009), the ribosomal deficiency was
measured after two rounds of small interfering (si)RNA
treatment, which lasted for 5 (or more) days. This raises the
concern that the initial direct effect of nucleostemin knockdown
could have triggered secondary responses during this period of
time, such as the observed ribosomal deficiency.
A recent discovery from my laboratory of a function of
nucleostemin in genome maintenance (Lin et al., 2013; Meng
et al., 2013) makes it possible to compare the time of onset of
DNA damage to the time of onset of ribosomal deficiency in
nucleostemin-knockdown cells. It is apparent that DNA damage
arises at the earliest time point of measurement, that is 12 hours
after the initiation of nucleostemin depletion, whereas no
significant effect on rRNA synthesis or nucleolar structure can
be noted up to 48 hours (Lin et al., 2014). This finding establishes
that DNA damage occurs considerably before ribosomal
perturbation in response to nucleostemin depletion. Of course,
the time-of-onset evidence alone does not prove that ribosomal
perturbation occurs secondarily as a result of DNA damage
following nucleostemin depletion, as the manifestation of
different phenotypes can take place in parallel and their times
of onset might depend on the kinetics of the underlying
mechanisms that lead to their activation. However, this finding
does raise a reasonable doubt on the immediacy of ribosomal
perturbation following nucleostemin depletion and acts as a
reminder of what has been noted for over 15 years, that is that the
transcription of rRNA is inhibited by the DNA-cross-linking
agent cisplatin (Jordan and Carmo-Fonseca, 1998). There again,
the question of whether rRNA transcription in cisplatin-treated
cells is affected directly by rDNA lesions or indirectly by the
DNA damage response signals has been long standing, as DNA
cross-linking agents, such as cisplatin, can directly inhibit
upstream binding factor (UBF) binding and RNA polymerase I
(Pol I) transcription by forming rDNA adducts and blocking
rDNA unwinding. A recent study by Calkins et al. addresses this
issue by using UV and c-irradiation, in addition to cisplatin, to
introduce DNA damage (Calkins et al., 2013). They report that
rRNA synthesis is also inhibited 24 hours after UV and c-
irradiation, and that the reverse signaling from cell cycle
progression to ribosomal synthesis involves mechanism
dependent on DNA-dependent protein kinase (DNA-PK) and
poly(ADP-ribose) polymerase 1 (PARP1). Another study in
support of this notion uses DNA lesions induced by c-irradiation
and shows that Pol I inhibition is not a direct effect of DNA
damage but is mediated by the complex between ataxia
telangiectasia mutated (ATM), Nijmegen breakage syndrome 1
(NBS1) and mediator of DNA damage checkpoint 1 (MDC1)
(Kruhlak et al., 2007).
As the end result of a gene depletion often does not reflect the
cellular process that is affected first, in order to conclude a causal
versus an associative relationship between a gene knockdown or
knockout event and the observed phenotypes, multiple lines of
evidence need to be considered, such as the sequence of onset of
events, direct interactions between the protein of interest and
pathway-specific components, functional rescue of phenotypic
deficits, and protein localization to the site of action. Taking this
into account, evidence for a direct role of nucleostemin in
maintaining genome or telomere integrity is provided by the early
onset of the observed DNA damage phenotypes, the direct
binding of nucleostemin to RAD51 (genome repair) or TRF1
(telomere protection), its ability to rescue DNA or telomere
damage that has been induced by stalling of replication or
disruption of telomere-binding complex (known as shelterin
dysfunction), respectively, as well as its physical recruitment to
DNA damage foci. Last but not least, the complexity of the
interconnecting signaling networks within cells and their versatile
responses to any perturbation event should at least alert, if not
prohibit, us biologists in drawing mechanistic conclusions based
on a few end phenotypes – such is a valuable lesson we learned
from working with nucleostemin.
Vertebrate and invertebrate nucleostemin tell two different
stories
When attempting to correlate the activities of nucleostemin in
different species, one must take into consideration that the
invertebrate nucleostemin (named GNL3) is a shared ortholog of
both nucleostemin and GNL3-like (GNL3L) in the vertebrates
(Tsai, 2011; Tsai and Meng, 2009). Although there is no shortage
of paralogous examples in biology, mammalian nucleostemin and
GNL3L are unique in that they exhibit distinct functions. It has
been shown that human nucleostemin lacks the ability to rescue
ribosomal dysregulation phenotypes that are associated with GNL3
deletion in Schizosaccharomyces pombe (Du et al., 2006) and
Caernohabditis elegans (Kudron and Reinke, 2008). Although the
failure to rescue GNL3 deficiency with mammalian nucleostemin
alone might simply reflect the inability of the latter to bind to the
invertebrate rRNA or ribosome, the fact that human GNL3L is able
to reverse the ribosomal phenotype of GNL3-depleted S. pombe
poses the interesting possibility that mammalian nucleostemin
might have functionally diverged from mammalian GNL3L and
invertebrate GNL3 (Du et al., 2006). Indeed, recent work has
shown that nucleostemin-knockdown triggers DNA damage
without causing a significant disturbance of ribosomal synthesis,
whereas depletion of GNL3L perturbs the processing of pre-rRNA
without causing DNA damage in human breast cancer cells (Lin
et al., 2014). On the basis of these studies, I propose the idea that
during the evolution of vertebrate species, GNL3L might have
retained the role of its ancestral gene in ribosome biosynthesis,
whereas, nucleostemin, the paralog that arose, acquired a new
function in genome protection. Another recent study has reported
that nucleostemin mutation in zebrafish (Danio rerio) causes a
reduction in the number of 60S ribosomes as well as of p53
stabilization, and that deletion of p53 can restore the decrease of
60S ribosomes in nucleostemin mutant fish and elevate 60S
ribosomes in wild-type fish (Essers et al., 2014). This finding
suggests that the ribosomal effect of nucleostemin-mutant fish can
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be explained by the effect of nucleostemin mutation in stabilizing
p53. Because nucleostemin and GNL3L proteins have 32.3%
identity in human and only 28.7% in zebrafish, it is also
conceivable that the functional divergence of nucleostemin and
GNL3L is still ongoing as the vertebrate species continue to
evolve. If so, zebrafish nucleostemin might have a greater
functional resemblance to invertebrate GNL3 than human
nucleostemin. Indeed, two major protein diversifications in the
GNL3/nucleostemin family appear to occur in the evolution of
vertebrate and mammalian species (Fig. 2).
Unlike nucleostemin and GNL3L, the story about their closest
kindred, GNL2 (also known as Nug2/Nog2 in yeast and NGP1 in
mammals), is quite different. GNL2 has always maintained the
status of a single gene subfamily throughout evolution and has
been known to function in the nuclear export of 60S ribosome, as
detected by the Rpl25–GFP reporter (Saveanu et al., 2001). A
recent study provides mechanistic insight into GNL2 function by
showing that it works as a ‘placeholder’ that binds to the juncture
of maturing pre-60S subunits and controls the proper timing in
the transfer of pre-60S ribosomes to the nuclear export adaptor
Nmd3 and the nucleolar export receptor Crm1 (Matsuo et al.,
2014). In this event, the GTP-binding state of GNL2 is crucial for
its binding to pre-60S ribosome, and its GTP hydrolysis is
required for its release from pre-60S ribosome and the subsequent
transfer of pre-60S ribosome to Nmd3. Notably, the GTPase
activity of GNL2 is stimulated by KCl as well as a
conformational change triggered by two pre-60S remodeling
factors, the Rea1 ATPase and its co-substrate Rsa4.
The amazing diversity of cell-cycle-arrest profiles of
nucleostemin-depleted cells
It is rather intriguing to see that loss of nucleostemin could have
been associated with cell cycle arrest at the G1/S, intra-S, G2/M
and M phases. Studies that reported a G1/S arrest phenotype
following nucleostemin-knockdown include those performed in
U2OS cells (Dai et al., 2008; Ma and Pederson, 2007), SW1710
cells (Nikpour et al., 2009), HeLa cells (Sijin et al., 2004), PC-3
cells (Liu et al., 2010) and bone marrow-derived stromal stem
cells (Jafarnejad et al., 2008). In contrast, the finding that
nucleostemin-depleted cells are arrested at the G2/M phase has
also been reported in several studies performed in U2OS cells
(Meng et al., 2008), HeLa cells (Romanova et al., 2009), 5637
cells (Nikpour et al., 2009) and mouse embryonic fibroblast cells
(MEFs) (Zhu et al., 2006). It is noted that the studies describing
G1/S arrest used cells with either wild-type or mutant forms of
p53, retinoblastoma, p16 and alternate reading frame (p14ARF)
protein (both encoded by CDKN2A), and studies describing G2/M
arrest also used cells with wild-type or mutant forms of p53,
retinoblastoma, p16 and p14ARF. This argues that none of these
tumor suppressor genes is the cause of the observed cell cycle
outcome of nucleostemin-depleted cells.
In a recent study from my laboratory, we observed a cell cycle
arrest upon nucleostemin knockdown in human breast cancer cells
(MDA-MB-231) after 12 hours, and found that, at this early time
point compared with other related studies, nucleostemin depletion
causes an increase in cells in S phase and a decrease of those in G2/
M, indicative of an intra-S-phase arrest (Lin et al., 2014). Most
importantly, our dose-dependent study revealed that the apparent
discrepancy with regard to the cell cycle effects of nucleostemin
depletion among different studies might be due to the level of
protein knockdown. A more efficient loss of nucleostemin causes
an early S-phase block with fewer cells in G2/M, whereas a less
efficient loss of nucleostemin results in arrest in late S and G2/M
with an increased number of G2/M cells (Lin et al., 2014). This
idea resonates with the finding of an earlier study showing that
HeLa cells with nucleostemin knockdown are unable to complete
DNA synthesis to pass through S phase, resulting in an increase in
the percentage of cells in G0/G1 and a concomitant decrease of S
phase cells (Sijin et al., 2004). Another point to keep in mind is that
a completely arrested S phase cell would not be able to incorporate
exogenous mitotic markers (e.g. BrdU), which have been used to
determine the percentage of cells in S phase as a measurement of
nucleostemin knockdown in some studies. However, just when a
more coherent picture on the cell cycle arrest profile of
nucleostemin-depleted cells appears to emerge, one study
published this year reports yet another new arrest phenotype in
the mitotic phase in nucleostemin-depleted HeLa cells (Maida
et al., 2014). At this stage, it is unclear whether this mitotic arrest
phenotype occurs as a stand-alone event or in association with one
of the many events caused by loss of nucleostemin, but it certainly
contradicts what we have found in U2OS cells, where
nucleostemin depletion causes cells to arrest at the G2/M phase
before cells enter the mitotic prophase (Meng et al., 2008). In the
same paper, the authors also showed that nucleostemin is a part of
the telomerase reverse transcriptase (hTERT)–Brahma-related
gene 1 (BRG1) complex.
p53 or no p53?
Our initial work on nucleostemin identified a physical connection
between nucleostemin and the p53 protein complex (Tsai and
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tree of GNL3, nucleostemin and
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provided.
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McKay, 2002). Although a number of subsequent studies have
reported that loss of nucleostemin turns on p53 to induce cell
cycle arrest in cells with wild-type p53, this finding did not
address whether p53 is necessary for the obligatory function of
nucleostemin in cell proliferation maintenance. There are some
studies that addressed this question by investigating the effect of
nucleostemin depletion in cells with wild-type and mutant p53,
but they reached opposite conclusions. In support of the p53-
dependency of nucleostemin activity, it has been shown that cell
cycle arrest or apoptosis that is triggered by knockdown or
knockout of nucleostemin can be completely or partially reversed
by p53 knockdown (Ma and Pederson, 2007; Paridaen et al.,
2011; Yamashita et al., 2013). Furthermore, nucleostemin has
been found to directly interact with MDM2 to modulate the
activity of p53 (Dai et al., 2008; Meng et al., 2008). In contrast,
some studies have not observed any role pf 53 and have prompted
the idea that an obligatory function of nucleostemin is required
for cell proliferation even in the absence of p53 – a claim that is
strongly supported by the observation that loss of p53 fails to
rescue the growth-deficient phenotype of nucleostemin depletion
in mouse blastocysts and MEFs (Beekman et al., 2006; Meng
et al., 2013). In fact, we have found that loss of p53 might even
accelerate the demise of nucleostemin-knockout MEF cells
(Meng et al., 2013). As the gatekeeper for the genome
integrity, most cytotoxic injuries converge on p53 to dispatch
one or more of its downstream events, including cell cycle arrest,
apoptosis, senescence and reduction in 60S ribosome numbers (as
recently reported by Essers et al., 2014), among others. Therefore,
it should not come as a surprise that p53 knockout might partially
alter the outcome of nucleostemin depletion, in particular if
events regulated by and downstream of p53 are used as the
readout. However, this apparent involvement of p53 will not
provide us with much insight into the specific mechanism of
nucleostemin action. One can even argue that the primary target
of nucleostemin, because it sits upstream of the p53 action,
should not be affected by p53-knockout initially, as such is the
case in DNA damage induced by nucleostemin knockout or
knockdown (Meng et al., 2013).
To date, the only evidence linking nucleostemin directly to the
p53 axis is its interaction with MDM2 (Dai et al., 2008; Ma and
Pederson, 2007; Meng et al., 2008; Tsai and McKay, 2002). In
our investigation of nucleostemin-mediated MDM2 regulation
(not on p53 stabilization), we found that, compared to wild-type,
mutants of nucleostemin that localize to the nucleoplasm more
strongly bind to MDM2 and retain it in the nucleoplasm, thereby
inhibiting its ubiquitylation and subsequent degradation, which
results in p53 activation (Meng et al., 2008). However, the effect
of nucleostemin-knockdown on MDM2 is much more evident in
cells that are under nucleolar stress than in normal growing cells
in interphase. Therefore, a more fitting model for the functional
interplay between nucleostemin and p53 is that the nucleostemin-
mediated regulation of MDM2 occurs mainly when the bulk of
nucleostemin is released from the nucleolus into the nucleoplasm,
which occurs during mitosis or nucleolar stress. Under conditions
in which the nucleolus is intact, the amount of nucleostemin in
the nucleoplasm is below the threshold of MDM2 and thus p53
regulation.
Nucleostemin brings a new perspective on self-renewal
The arguments presented so far indicate that most of the activities
of nucleostemin reported to date, including genome and telomere
protection, MDM2–p53 regulation, ribosomal synthesis and cell
cycle regulation, can be explained without having to evoke the
concept of multi-functionality (as compared to mono- or oligo-
functionality) (Fig. 3). The obligatory function of nucleostemin
in maintaining cell proliferation under normal growing conditions
is most consistent with its role in protecting the genome from
DNA damage, which is fulfilled by the nucleoplasmic pool of
nucleostemin during genome replication in S phase. How DNA
damage signals trigger nucleostemin localization to the site of
damage is an important aspect in understanding the biology of
nucleostemin in genome protection. The perceived signals that
lead to the accrual of nucleostemin on damaged DNA in the
nucleoplasm remain speculative but likely involve different sets
of control that are distinct from those described for its nucleolar
targeting and retention (see Box 1). In actively dividing cells with
rRNAs
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Fig. 3. Model of the mechanism underlying nucleostemin function. The central panel represents nucleostemin activity in normal growing interphase cells,
whereas the left and right panels represent cells under increased genotoxic or nucleolar stress, respectively. The primary activity of nucleostemin is to
protect against DNA damage caused by genome replication (indicated by the replication fork) in normal growing cells or by exogenous sources of radiation or
chemicals (indicated by the lightning sign) in cells under genotoxic stress. In response to nucleolar stress, the release of nucleostemin from the nucleolus
stabilizes MDM2 and prevents p53-mediated activation of its downstream targets involved in cell cycle regulation (represented by p21) and apoptosis
(represented by BAX). Rounded rectangles, yellow circles and gray circles represent the cell, nucleus, and nucleolus, respectively. The nucleolus is divided
into two domains that are either rich in or deficient in rRNAs (blue wave symbol). Ub, ubiquitin; 26S, 26S-proteasome complex; green double helix,
p53-regulated genes.
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intact nucleoli, loss of nucleostemin triggers replication-
associated DNA damage, which then leads to S phase arrest,
possibly through the ataxia telangiectasia and Rad3-related
(ATR)–checkpoint kinase 1 (Chk1) and ATM–checkpoint
kinase 2 (Chk2) pathways, which might activate p53, if
available. When the nucleolus is disassembled under nucleolar
stress or during mitosis, nucleostemin is released en masse from
the nucleolus into the nucleoplasm. This sudden increase of
nucleostemin in the nucleoplasm allows it to interact with and
stabilize MDM2 independently of its function in DNA repair.
Although invertebrate nucleostemin might indeed have a role in
ribosomal synthesis, in mammalian cells, this activity has been
inherited by GNL3L and not by nucleostemin. The apparent
ribosomal defect that is seen upon nucleostemin depletion in
mammalian cells might in fact be a result of increased DNA
damage and subsequent cell cycle arrest.
This newly revealed activity of nucleostemin in genome
protection, in conjunction with its established expression and
importance in normal and cancerous stem cells, suggests that,
compared with their differentiated progeny, mitotically active
stem or progenitor cells might be differentially equipped to repair
DNA damage caused by genome replication. Given that stem
cells form the cornerstone in embryonic organogenesis and adult
tissue homeostasis, it makes perfect sense that the integrity of
their genome must be kept at the most pristine quality. As a
testament to the importance of the DNA damage response and
repair proteins in stem cell maintenance, defects in many of these
proteins often result in phenotypes that can be traced to stem cell
dysfunction, including premature aging, embryonic lethality,
hematopoietic deficiency, increased UV and radiation sensitivity,
and elevated cancer incidence. With regard to damage reduction,
several mechanisms that might help achieve this goal have been
proposed, including a specific microenvironment with low
oxygen levels to minimize oxidative stress, a mitotically
quiescent state that avoids replicative stress, and limited
reactive oxygen species production from cell-intrinsic
metabolism (Orford and Scadden, 2008). With regard to
response and repair, damaged stem cells might choose to self-
sacrifice for a greater good or to respond to and repair damaged
DNA more efficiently (Blanpain et al., 2011). So which factor
dictates the behavior of stem cells under DNA damage
conditions? The answer might lie in the tissue origins of the cell.
Cord-blood-derived human embryonic HSCs (Milyavsky et al.,
2010), interfollicular basal stem cells (Finlan et al., 2006) and
intestinal stem cells are among those cell types that preferentially
choose to commit suicide in response DNA damage. Their
altruistic behavior might be driven mechanistically by an
enhanced activity in the pro-apoptotic network or the lack of
DNA repair activity. By comparison, more types of stem cells
choose to live, as has been shown for adult hematopoietic stem
cells (HSCs) (Mohrin et al., 2010), epidermal stem cells (Rachidi
et al., 2007), hair follicle stem cells (Sotiropoulou et al., 2010)
and mammary stem cells, as well as CSCs in breast cancer,
leukemia and glioblastoma multiforme (Bao et al., 2006; Diehn
et al., 2009; Jordan et al., 2006; Li et al., 2008). These cells might
survive cell-intrinsic or extrinsic genotoxic insults through
engaging specialized protective mechanisms that suppress the
apoptotic pathway or promote the efficiency of DNA damage
repair machinery – an area which nucleostemin might make its
contribution in. Not surprisingly, stem cells also rely on different
mechanisms for repair depending on their mitotic status, for
example, non-homologous end-joining (NHEJ) is used by
quiescent HSCs and homologous recombination is used by
mitotically active HSCs (Mohrin et al., 2010). Some members in
the core DNA damage response and repair pathway show particular
enrichment in mitotically hyperactive cells. Breast cancer
susceptibility gene 1 (BRCA1), a tumor suppressor with functions
in DNA damage repair, the centrosome and mitotic spindle, is most
highly expressed in the embryonic neuroepithelium, which contains
highly proliferative progenitors (Lane et al., 1995). Deletion of this
gene in the developing neural epithelium results in severe agenesis
of the neocortex, hippocampus, cerebellum and olfactory bulb (Pao
et al., 2014), which to some extent resembles the phenotype of
nestin-driven nucleostemin-knockout mice (Meng et al., 2013).
Indeed, when it comes to supporting the idea of specialized genome-
protective mechanisms in self-renewing cells, nucleostemin does
not stand alone.
Conclusion
Taking all that have been discussed in consideration, it is logical
to think that nucleostemin exercises a primary and constitutive
activity in safeguarding against replicative DNA damage and an
induced activity in stabilizing MDM2 under conditions of
nucleolar stress. Although invertebrate nucleostemin might
function in the biogenesis of ribosome, the reported effect of
nucleostemin depletion on rRNA synthesis in mammalian cells
might rather represent a late event that occurs secondarily to cell
cycle arrest. The discovery of its function in maintaining the
integrity of replicating genome signifies a new chapter in the life
of nucleostemin as well as in our understanding of self-renewal.
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